Abstract
Levodopa-carbidopa intestinal gel therapy in Parkinson’s disease: Procedure complications
Highlights
Parkinson’s disease (PD) is a chronic and progressive movement disorder and the second-most common neurodegenerative disorder in the world [1,2,3,4]
This study aimed to investigate the percutaneous endoscopic transgastric jejunostomy (PEG-J) use and the occurrence of procedural complications in a group of patients diagnosed with PD Hoehn and Jahr 3 and 4 stages, receiving levodopa-carbidopa intestinal gel (LCIG) therapy
A quarter of the subjects in this group had interrupted the therapy after a median time of one year, mainly due to patients, or patients’ relative request
Summary
Parkinson’s disease (PD) is a chronic and progressive movement disorder and the second-most common neurodegenerative disorder in the world [1,2,3,4]. PD is associated with progressive disability and mobility-related impairments with increased mortality and decreased quality of life for patients and their families [5,6,7,8,9,10]. The symptomatology is dominated by the motor fluctuations and the alteration between „on” (mobility often with dyskinesia) and „off” (immobility) episodes [4]. Levodopa and carbidopa represent the primary therapy of PD. Because their absorption is made in the small bowel, a decreased level of absorption
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
